Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bad Kreuznach – page 5

739 clinical trials in Bad Kreuznach, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bad Kreuznach at a glance
739
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

739 trials in Bad Kreuznach

Open in trial search

Hepatic fibrosis+2

Recruiting

Study on Efruxifermin for Patients with Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH) and Fibrosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Efruxifermin
  • Sponsor:Akero Therapeutics Inc.

Study on Clazakizumab for Heart Disease in Adults with End-Stage Kidney Disease on Dialysis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Clazakizumab
  • Sponsor:CSL Behring LLC

IgA nephropathy

Recruiting

A study to evaluate the effect of zigakibart in adults with IgA nephropathy

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Zigakibart
  • Sponsor:Novartis Pharma AG

Study on Bortezomib and Drug Combination for Children with High-Risk Relapsed Acute Lymphoblastic Leukemia (ALL)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Bortezomib
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Study on the Safety and Effectiveness of EIK1001 and Pembrolizumab for Patients with Advanced Melanoma

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Eikon Therapeutics Inc.

Study on N-Acetyl-L-Leucine for Patients with Niemann-Pick Disease Type C

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:L-Acetylleucine
  • Sponsor:Intrabio Limited

Study of Camizestrant for Patients with ER+/HER2- Early Breast Cancer After 2 Years of Standard Endocrine Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:AstraZeneca AB

Breast cancer

Recruiting

Study of Tersolisib and a drug combination for adults with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Eli Lilly & Co.

Comparison of rocbrutinib versus pirtobrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pirtobrutinib
  • Sponsor:Newave Pharmaceutical Inc.

Phase 3 Study of GSK6042981 versus Imatinib in Adults with Previously Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib Mesilate
  • Sponsor:Glaxosmithkline Research & Development Limited

Triple vs dual therapy with rosuvastatin, ezetimibe and bempedoic acid in patients with atherosclerotic heart disease and high cholesterol undergoing revascularisation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bempedoic Acid
  • Sponsor:Medical University Of Graz

A Study of Setidegrasib with Chemotherapy Drug Combination as First‑Line Treatment in Adults with KRAS G12D‑mutated Metastatic Pancreatic Cancer

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ASP3082
  • Sponsor:Astellas Pharma Global Development Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bad Kreuznach

What the registry says about research in the country

01 Neonatal Care Research

Clinical trials focusing on improving oxygen administration in extremely preterm infants, investigating automated versus manual control systems to enhance respiratory support outcomes.

  • Respiratory Support Management
  • Oxygen Therapy Control
  • Premature Birth Complications

This innovative research aims to evaluate the effectiveness of closed-loop automatic control systems in preventing complications such as ROP, NEC, and BPD while monitoring long-term neurocognitive development in premature babies.

02 Pediatric Intensive Care

Studies examining advanced respiratory support technologies for infants born between 23 and 27 weeks of gestational age, with a focus on optimizing ventilation strategies.

  • Mechanical Ventilation
  • CPAP Management
  • Oxygen Therapy Safety

The research, supported by the German Federal Ministry for Education and Research, explores improvements in neonatal intensive care practices to enhance survival rates and reduce complications.

03 Long-term Developmental Outcomes

Investigation into the long-term effects of oxygen therapy management on neurocognitive development in premature infants, tracked over a 24-month period.

  • Developmental Assessment
  • Mortality Prevention
  • Quality of Life Improvement

This comprehensive study evaluates both immediate medical outcomes and extended developmental progress in extremely preterm infants receiving different oxygen administration methods.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.